Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) – Drugs In Development, 2024 report and make more profitable business decisions.
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is an inherited metabolic disease caused by an absence or malfunctioning of certain enzymes needed to break down molecules called glycosaminoglycans (GAGs). Symptoms include seizures, hyperactivity, liver and spleen enlargement, severe diarrhea or constipation, and enlargement of tonsils and adenoids. Treatment includes enzyme replacement therapy (ERT).
The Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) drugs in development market research report provide comprehensive information on the therapeutics under development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 32 molecules, with 31 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Allievex CorpAmicus Therapeutics Inc
ArmaGen Inc
BioStrategies LC
Denali Therapeutics Inc
Esteve Pharmaceuticals SA
GC Biopharma Corp
JCR Pharmaceuticals Co Ltd
Jupiter Neurosciences Inc
Lacerta Therapeutics Inc
Lysogene SAS
M6P Therapeutics
Neurogt Inc
Orchard Therapeutics Plc
Phoenix Nest Inc
Seelos Therapeutics
Inc.
Swedish Orphan Biovitrum AB
Tega Therapeutics Inc
Ultragenyx Pharmaceutical Inc
University of Montreal
Table of Contents
Table
Figures
Frequently asked questions